"Since her arrival at Onyx, Laura has overseen the expansion of key corporate capabilities, guided our business planning, and strengthened our financial position," said Renton. "Laura's superb leadership skills and diverse experience will help ensure Onyx continues to deliver on our mission to improve the lives of people living with cancer."
Kelley, previously vice president of sales, joined Onyx in September 2004. While at Onyx, Kelley established its U.S. sales organization and managed, with the company's collaborator, Bayer, the successful launch of Nexavar, a targeted oncology agent approved for the treatment of advanced kidney cancer. From 1994 to 2004, Kelley served in various senior sales and marketing positions at Chiron Corporation, including vice president, North American sales for the company's biopharmaceutical division. Previously Kelley was vice president of sales at Immunex Corporation and held various sales management positions at Adria Laboratories. Kelley earned his B.A. from the University of the Pacific. He is a member of the Board of Directors of the William S. Graham Foundation for Melanoma Research.
"As a veteran oncology executive, Randy moved swiftly to build Onyx's commercial infrastructure from the ground up," said Renton. "Randy's dedication, team-building skills, and commitment to performance will be instrumental in driving Nexavar's planned commercial launch in liver cancer and beyond."
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing
innovative therapies that target the molecular mechanisms that cause
cancer. The company is commer
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved